Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
5.295 USD 0.07 ( 1.44%)
Last update at 2026-11-09T15:09:00Z
VOLUME
1629
Market Cap
45.62M

Momentum Score

…

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
5.21
Low
5.29
High
52 Week Price Range
1.85
Low
6.26
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cumberland Pharmaceuticals is a specialty branded pharmaceutical company that develops, markets and acquires hospital and acute-care prescription products and related services. Its long-term growth may be driven by new product approvals and in-licensing/acquisition opportunities, expanded hospital adoption, and lifecycle management of existing brands. Investors may find it attractive due to recurring demand from institutional customers, a focused commercial model, and a history of incremental portfolio expansion.
Primary risks include reliance on a small number of marketed products, vulnerability to competition and reimbursement changes, and execution risk from acquisitions and development.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
5.22
Dividend Yield
-
Revenue TTM
44.52M
Revenue Per Share
3.00
Gross Profit TTM
37.85M
Debt / Equity
0.41
ROE
-12.17%
Net Debt
-1.26M
ROCE
-6.97%
Diluted EPS TTM
-0.19

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -2.82M -6.47M -6.28M -5.58M -5.56M
Minority interest 0.03M -0.04M 0.06M 0.08M 0.10M
Net income -2.84M -6.48M -6.28M -5.65M -5.60M
Selling general administrative 11.95M 11.13M 10.65M 10.18M 9.78M
Selling and marketing expenses 19.10M 17.02M 18.45M 16.66M 15.02M
Gross profit 37.85M 31.28M 33.49M 32.89M 27.17M
Reconciled depreciation 5.29M 6.04M 4.21M 5.33M 4.61M
Ebit -2.79M -5.86M -5.62M -5.70M -7.68M
Ebitda 2.49M 0.18M 2.49M -0.28M -0.86M
Depreciation and amortization 5.29M 6.04M 8.10M 5.43M 6.82M
Operating income -2.79M -6.43M -9.55M -5.70M -7.68M
Other operating expenses 47.31M 44.30M 49.11M 47.72M 43.66M
Interest expense 0.50M 0.61M 0.67M 0.59M 0.10M
Tax provision 0.04M -0.02M 0.07M 0.07M 0.03M
Interest income 0.48M 0.33M 0.25M 0.10M 0.03M
Net interest income -0.02M -0.27M -0.42M -0.49M -0.07M
Income tax expense 0.04M -0.02M 0.05M 0.07M 0.03M
Total revenue 44.52M 37.87M 39.55M 42.01M 35.99M
Total operating expenses 40.65M 37.71M 43.04M 38.60M 34.85M
Cost of revenue 6.67M 6.59M 6.07M 9.12M 8.81M
Total other income expense net -0.03M -0.03M 3.27M 0.12M 2.12M
Discontinued operations - - - - 1.99M
Net income from continuing ops -2.86M -6.44M -2.49M -5.65M -5.60M
Net income applicable to common shares - - - -5.57M -3.51M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 76.82M 75.58M 81.78M 92.93M 84.46M
Intangible assets 14.03M 17.97M 22.61M 30.59M 23.95M
Other current assets 2.45M 2.79M 3.03M 3.55M 3.34M
Total liab 52.28M 53.04M 52.52M 56.95M 41.86M
Total stockholder equity 24.88M 22.85M 29.60M 36.27M 42.81M
Other current liab 17.71M 12.25M 13.60M 17.59M 8.67M
Common stock 51.68M 46.82M 47.09M 47.47M 48.45M
Capital stock 51.68M 46.82M 47.09M 47.47M 48.45M
Retained earnings -26.80M -23.97M -17.49M -11.21M -5.64M
Other liab - - - 7.59M 7.49M
Good will 0.91M 0.91M 0.91M 0.91M 0.88M
Other assets - 75583334.42M - 10.05M 12.47M
Cash 11.44M 17.96M 18.32M 19.76M 27.04M
Total current liabilities 36.74M 31.62M 27.98M 28.58M 19.28M
Net debt -1.26M 2.61M 0.11M 1.20M -10.98M
Short term debt 0.47M 5.46M 0.35M 0.17M 0.97M
Short long term debt - 5.10M - - -
Short long term debt total 10.18M 20.57M 18.43M 20.96M 16.06M
Other stockholder equity - - - - -0.21M
Property plant equipment - - - 5.50M 1.47M
Total current assets 37.06M 36.45M 35.71M 45.87M 45.69M
Long term investments 3.99M 0.00M - - -
Net tangible assets - - - 4.76M 17.98M
Net receivables 16.94M 11.70M 9.76M 13.16M 6.88M
Long term debt 5.24M 10.18M 12.78M 16.20M 15.00M
Inventory 6.23M 4.00M 4.61M 9.40M 8.43M
Accounts payable 18.57M 13.91M 14.04M 10.82M 9.64M
Non currrent assets other 12.23M 13.79M 15.50M 10.05M 12.47M
Non current assets total 39.76M 39.13M 46.06M 47.05M 38.77M
Capital lease obligations 4.94M 5.30M 5.64M 4.76M 1.06M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -4.48M 0.06M -1.01M -13.67M -0.50M
Change to liabilities - - - 14.54M -0.76M
Total cashflows from investing activities -4.71M 0.06M -0.11M -13.67M -0.50M
Net borrowings -10.04M 2.49M -3.42M 1.20M 1.20M
Total cash from financing activities -6.75M 0.20M -7.42M -2.06M -3.55M
Change to operating activities - - - 1.11M -1.38M
Net income -2.84M -6.48M -6.28M -5.65M -3.60M
Change in cash -6.52M -0.36M -1.44M -7.28M 2.29M
Begin period cash flow 17.96M 18.32M 19.76M 27.04M 24.75M
End period cash flow 11.44M 17.96M 18.32M 19.76M 27.04M
Total cash from operating activities 4.93M -0.61M 6.09M 8.45M 6.34M
Issuance of capital stock 5.27M 0.00M - - -
Depreciation 5.29M 6.04M 5.77M 5.33M 4.61M
Other cashflows from investing activities -0.05M 0.24M 0.35M 1.90M -0.15M
Change to inventory 2.24M 2.41M -0.02M 1.38M 4.82M
Change to account receivables -5.24M -1.94M 3.40M -6.12M 5.50M
Sale purchase of stock -0.26M -0.58M -0.74M -1.05M -1.39M
Other cashflows from financing activities 3.55M -1.72M -3.27M 50.69M 56.83M
Change to netincome - - - -1.74M -2.94M
Capital expenditures 0.10M 0.18M 0.45M 2.07M 0.35M
Change in working capital 2.16M 1.29M 4.63M 10.97M 8.18M
Stock based compensation 0.41M 0.30M 0.37M 0.45M 0.74M
Other non cash items 0.32M -1.77M 1.60M -2.64M -3.39M
Free cash flow 4.83M -0.79M 5.64M 6.38M 5.99M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CPIX
Cumberland Pharmaceuticals Inc		 0.07
1.44%		 5.29 - 50.00 1.02 1.92 1.04 15.61
MKKGY
Merck KGaA ADR		 0.49
1.48%		 33.66 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.05
0.24%		 20.97 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 0.50
1.19%		 42.35 - 10.66 0.01 1.16 2.94 23.11

Profile*

Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

1600 West End Avenue, Nashville, TN, United States, 37203

615 255 0068

https://www.cumberlandpharma.com

93

Name Title Year Born
Mr. A. J. Kazimi MBA Founder, Chairman, Pres & CEO 1958
Mr. John Michael Hamm Sr. Director of Fin. & Accounting and CFO 1957
Mr. James Lowrance Herman Exec. VP of National Accounts & Chief Compliance Officer 1955
Ms. Jean W. Marstiller Sr. VP of Admin. Services & Corp. Sec. 1950
Ms. Cindy B. Patton Sr. Director of Field Marketing 1953
Mr. Adam S. Mostafa Managing Director 1980
Mr. Todd M. Anthony VP of Organizational Devel. NA
Ms. Erin Smith Gull Sr. Corp. Relations Associate NA
Mr. A. J. Kazimi MBA Founder, Chairman, President & CEO 1958
Mr. John Michael Hamm VP & CFO 1956

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.19%

  • Communication Services

    -0.04%

  • Consumer Cyclical

    +0.27%

  • Consumer Defensive

    -0.21%

  • Energy

    +1.16%

  • Financial Services

    +0.81%

  • Healthcare

    +0.03%

  • Industrials

    +1.64%

  • Real Estate

    +0.06%

  • Technology

    +0.38%

  • Utilities

    +0.68%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…